Advice
Following a full submission
Buprenorphine transdermal patch (BuTrans) is not recommended for use within NHS Scotland for the treatment of severe opioid responsive pain conditions which are not adequately responding to non-opioid analgesics. There was a lack of evidence of comparative efficacy with a clinically relevant treatment for chronic pain available in the UK.
The economic case has not been demonstrated. The licence holder has indicated their decision to resubmit.
Download detailed advice41KB (PDF)
Medicine details
- Medicine name:
- Buprenorphine transdermal patches (BuTrans)
- SMC ID:
- 234/06
- Indication:
- Severe opioid responsive pain conditions which are not adequately responding to non-opioid analgesics
- Pharmaceutical company
- Napp Pharmaceuticals Ltd
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 13 February 2006